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Abstract
Background: Essential hypertension has been extensively reported to cause endothelial dysfunction. The aim of
this study was to evaluate the effects of barnidipine or lercanidipine, in addition to losartan, on some parameters
indicative of endothelial damage and oxidative stress in hypertensive, type 2 diabetic patients.
Methods: One hundred and fifty one patients were randomised to barnidipine, 20 mg/day, or lercanidipine,
20 mg/day, both in addition to losartan, 100 mg/day, for 6 months. We assessed BP every month, in addition,
patients underwent ambulatory blood pressure monitoring (ABPM). We also assessed: fasting plasma glucose (FPG),
glycated hemoglobin (HbA1c), some markers such as high-sensitivity C-reactive protein (Hs-CRP), tumor necrosis
factor-α (TNF-α), metalloproteinase-2 (MMP-2) and -9 (MMP-9), soluble vascular adhesion protein-1 (sVCAM-1),
soluble intercellular adhesion protein-1 (sICAM-1), isoprostanes and paraoxonase-1 (PON-1).
Results: Both barnidipine and lercanidipine resulted in a significant reduction in blood pressure, even if the
reduction obtained with barnidipine + losartan was greater than that obtained with lercanidipine + losartan. Data
recorded with ABPM also showed a similar trend. Barnidipine + losartan reduced the levels of Hs-CRP, TNF-α,
sVCAM-1, sICAM-1, and isoprostanes both compared to baseline and to lercanidipine + losartan.
Conclusions: Barnidipine + losartan gave an improvement of some parameters indicative of endothelial damage
and oxidative stress in diabetic and hypertensive patients.
Trial registration: NCT02064218, ClinicalTrials.gov
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Background
Essential hypertension has been extensively reported to
cause endothelial dysfunction, characterised by unbalanced
vasodilation and vasoconstriction, increased oxidative
stress, vascular inflammation, alteration of prothrombotic
and fibrinolytic pathways, abnormal smooth muscle cell
proliferation, and impaired repair mechanisms [1]. In par-
ticular, metalloproteinases (MMPs) have been implicated
as a cardiovascular risk factor [2], and a large body of evi-
dence asserts the role of MMPs in atherosclerosis [3]. It is
well known that the main cause of acute coronary syn-
dromes is the plaque disruption with subsequent superim-
posed intracoronary thrombus leading to prolonged
coronary obstruction [4]. Both MMP-2 and MMP-9 are
synthesized and secreted locally in atherosclerotic lesions,
predominantly by monocyte derived macrophages and
endothelial cells [5]. It has been already reported that cir-
culating MMPs levels are elevated in hypertensive patients
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[6], in obese subjects [7], in patients with acute coronary
syndrome [8], with type 2 diabetes mellitus [9] or with
combined dyslipidemia [10]. According to latest European
Cardiology Society guidelines, combination of anti-
hypertensive therapy provides greater blood pressure low-
ering effects than single-agent therapy, and the added
benefit of an angiotensin receptor blocker (ARB) and dihy-
dropyridine calcium channel blocker (CCB) combination
is a minor incidence of adverse events [11]. Angiotensin
receptor blocker and CCB combination also proved to
have some pleiotropic effects such as improvement of in-
sulin sensitivity [12], and prevention of new episodes of
atrial fibrillation in hypertensive diabetic patients [13].
However, not all CCBs have the same properties, and
studies comparing CCBs effects on inflammations are
lacking. Among CCBs, barnidipine and lercanidipine
proved to be the ones with longer lasting effect.
In particular barnidipine hydrochloride differs from
other CCBs, such as nifedipine or nisoldipine, in its
water solubility. In vitro studies in rats have revealed
that barnidipine metabolism is catalyzed by liver micro-
somes, specifically by cytochrome P450. The pharmaco-
logical effects of barnidipine are longer lasting than
those of other CCBs such as nifedipine; sustained occu-
pancy of dihydropyridine receptors by barnidipine was
observed in vitro as well as in vivo [14].
Lercanidipine, instead, is a lipophilic, dihydropyridine
calcium antagonist, and its high membrane partition co-
efficient provides a long-lasting effect at receptor and
membrane levels, allowing for once daily administration.
Its slow onset of action helps to avoid reflex tachycardia
associated with other dihydropyridines [15].
The aim of this study was to evaluate the effects of
barnidipine or lercanidipine, in addition to losartan, on
some parameters indicative of endothelial damage and




This randomised, double-blind, controlled study was con-
ducted at the Department of Internal Medicine and Ther-
apeutics, IRCCS Policlinico San Matteo, PAVIA, Italy.
The study protocol was conducted in accordance with
the Declaration of Helsinki and its amendments, and the
Good Clinical Practice Guidelines. It was approved by
the IRCCS Policlinico San Matteo Ethical Committee
and all patients provided written informed consent prior
to entering the study. TRIAL REGISTRATION: Clinical
Trials.gov NCT02064218.
Patients
We enrolled 151 hypertensive patients with mild to
moderate hypertension, type 2 diabetes mellitus,
normocholesterolemic [low density lipoprotein choles-
terol (LDL-C) < 160 mg/dl], overweight outpatients,
aged ≥ 18 of either sex (Table 1).
Patients were evaluated for eligibility according to the
following inclusion criteria:
 systolic blood pressure (SBP) ≥ 140 mmHg <
180 mmHg and/or diastolic blood pressure (DBP) ≥
90 mmHg < 105 mmHg
 in therapy with losartan
 well controlled type 2 diabetes mellitus (HbA1c ≤
7.5 %)
The exclusion criteria were secondary hypertension,
severe hypertension (SBP ≥ 180 mmHg or DBP ≥
105 mmHg), hypertrophic cardiomyopathies due to eti-
ologies other than hypertension, history of heart failure,
history of angina, stroke, transient ischemic cerebral at-
tack, coronary artery bypass surgery or myocardial in-
farction any time prior to visit 1, concurrent known
symptomatic arrhythmia, liver dysfunction (AST or ALT
values exceeding 2-fold the upper limit), creatinine >
1.5 mg/dl, known hypersensitivity to the study drugs.
Pregnant women as well as women of childbearing po-
tential were excluded.
Suitable subjects, identified from review of case notes
and/or computerized clinic registers were contacted per-
sonally or by telephone. No changes in anti-diabetic
treatment happened during the study.
Treatments
The patients fulfilling the inclusion and exclusion cri-
teria, were randomised to lercanidipine 20 mg/day, or
barnidipine, 20 mg/day, in addition to losartan 100 mg/
day for 6 months. Both lercanidipine, and barnidipine
were supplied as identical, opaque, white capsules in
coded bottles to ensure the blind status of the study.







Age (years) 60.5 ± 8.9 60.7 ± 8.8
Sex (male/female) 37/38 36/40
BMI (Kg/m2) 28.5 ± 1.3 28.2 ± 1.1
Duration of diabetes
(months)
9.3 ± 7.2 9.1 ± 7.1
Duration of hypertension
(months)
6.4 ± 3.6 6.3 ± 3.5
eGFR (ml/min/1.73 m2) 84.1 ± 8.5 82.5 ± 7.6
Data are means ± SD
BMI body mass index, eGFR estimated glomerular filtration rate
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Randomisation was done using a drawing of envelopes
containing randomisation codes prepared by a statisti-
cian. A copy of the code was provided only to the re-
sponsible person performing the statistical analysis. The
code was only broken after database lock, but could have
been broken for individual subjects in cases of an emer-
gency. Medication compliance was assessed by counting
the number of pills returned at the time of specified
clinic visits. At baseline, we weighed participants and
gave them a bottle containing a supply of the study
medication for at least 100 days. Throughout the study,
we instructed patients to take their first dose of new
medication on the day after they were given the study
medication. At the same time, all unused medication
was retrieved for inventory. All medications were pro-
vided free of charge.
Diet and exercise
Patients were already following a controlled-energy diet
(near 600 Kcal daily deficit) based on American Heart
Association (AHA) recommendations [16] that included
50 % of calories from carbohydrates, 30 % from fat (6 %
saturated), and 20 % from proteins, with a maximum
cholesterol content of 300 mg/day and 35 g/day of fibre.
Patients were not treated with vitamins or mineral prep-
arations during the study.
Standard diet advice was given by a dietitian and/or
specialist doctor. Dietitian and/or specialist doctor peri-
odically provided instruction on dietary intake recording
procedures as part of a behaviour modification program
and then later used the subject’s food diaries for counsel-
ling. Individuals were also encouraged to increase their
physical activity by walking briskly for 20 to 30 min, 3 to
5 times per week, or by cycling. The recommended
changes in physical activity throughout the study were
not assessed.
Assessments
Before starting the study, all patients underwent an ini-
tial screening assessment that included a medical his-
tory, physical examination, vital signs, and a 12-lead
electrocardiogram. We assessed blood pressure (BP)
every month, in addition, patients underwent ambula-
tory blood pressure monitoring (ABPM), at baseline
and at the end of the study. We also collected blood
sample to assess: fasting plasma glucose (FPG), glycated
hemoglobin (HbA1c), some markers indicative of endo-
thelial damage such as high-sensitivity C-reactive
protein (Hs-CRP), tumor necrosis factor-α (TNF-α),
metalloproteinase-2 (MMP-2) and -9 (MMP-9), soluble
vascular adhesion protein-1 (sVCAM-1), soluble inter-
cellular adhesion protein-1 (sICAM-1). We also evalu-
ated some markers of oxidative stress such as
isoprostanes and paraoxonase-1 (PON-1).
All plasmatic parameters were determined after a 12-h
overnight fast. Venous blood samples were taken for all
patients between 08.00 and 09.00 A.M. We used plasma
obtained by addition of Na2-EDTA, 1 mg/ml, and centri-
fuged at 3000 g for 15 min at 4 °C. Immediately after
centrifugation, the plasma samples were frozen and
stored at -80 °C for no more than 3 months. All mea-
surements were performed in a central laboratory.
Blood pressure measurements were obtained from
each patient (left arm) in the sitting position by physi-
cians blinded to treatment using a standard mercury
sphygmomanometer (Erkameter 3000; ERKA, Bad Tolz,
Germany) (Korotkoff I and V) with a cuff of appropriate
size. Blood pressure has been always measured in the
morning before daily drug intake (i.e, at trough 22-24 h
after dosing) and after the subject has rested 10 min in a
quiet room. Three successive BP readings were obtained
at 1-min intervals and averaged.
Heart rate was measured by pulse palpation for 30 s,
just before the BP measurements.
Body weight was measured with light clothes and
without shoes and BMI was calculated as the weight in
Kg divided by height in m squared.
Glycated hemoglobin level was measured by a high
performance liquid chromatography method (DIAMAT,
Bio-Rad, USA; normal values 4.2-6.2 %), with intra- and
interassay coefficients of variation (CsV) of < 2 % [17].
Plasma glucose was assayed by glucose-oxidase method
(GOD/PAP, Roche Diagnostics, Mannheim, Germany)
with intra- and interassay CsV of < 2 % [18].
High sensitivity C-reactive protein was measured with
use of latex-enhanced immunonephelometric assays on
a BN II analyser (Dade Behring, Newark, Delaware,
USA). The intra- and interassay CsV were 5.7 % and
1.3 %, respectively [19].
Tumor necrosis factor-α level was assessed using com-
mercially available ELISA kits according to manufac-
turer’s instructions (Titer-Zyme EIA kit; Assay Designs,
Ann Arbor, MI). Intraassay CsV were 4.5 % for low- and
3.6 % for high-concentration samples, whereas the inter-
assay CsV were 6.0 % for low and 11.8 % for high-
concentration samples, respectively [20].
Metalloproteinase-2, and MMP-9 levels were deter-
mined by a two-site ELISA methods using commercial
reagents (Amersham Biosciences, Uppsala, Sweden). The
intra- and interassay CsV for measuring MMP-2 levels
were 5.4 %, and 8.3 %, respectively [21]. The intra- and
interassay CsV to evaluate MMP-9 levels were 4.9 %,
and 8.6 % [22].
Soluble intercellular adhesion molecule-1 and sVCAM-
1 were assessed using commercially available ELISA kits
according to manufacturer instructions (R & D Systems,
Minneapolis, MN, USA). The intra- and interassay CsV
were < 10 %, respectively [23, 24].
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The level of isoprostanes in serum was determined by
commercially available ELISA kit (Cayman Chemicals,
Ann Arbor, Mich) [25].
Paraoxonase 1 activity in serum was measured using
paraoxon as a substrate in the presence of 2 mM Ca+2 in
100 mM Tris-HCL buffer (pH = 8.0) [26].
Ambulatory blood pressure monitoring
Twenty-four-hour BP and HR were evaluated by non-
invasive automatic monitoring Spacelabs model 90207:
Redmond, WA, USA) [27]. The interval between two
subsequent measurements was 20 min from 07:00 to
23:00 h, and 30 min from 23:00 to 07:00 h, with a total
number of about 64 measurements. Subjects were
instructed to remain motionless and to record their ac-
tivity on a diary sheet. The recorder automatically dis-
carded false readings (e.g. arm in motion or sound
interference during recording). Furthermore, additional
readings were rejected during computer analysis if differ-
ential BP was < 20 mmHg, DBP was < 50 mmHg or SBP
was > 260 mmHg in isolated readings. Less than 15 % of
the total readings were rejected as artefacts. Recordings
were only included in the study if at least 85 % of the
maximal number of 64 readings during the 24-h period
passed the deletion criteria. We calculated the following
values from the 24-h BP profiles: mean 24-h SBP and
DBP values, mean daytime SBP and DBP values, mean
night-time SBP and DBP values, and the absolute
difference between mean daytime and night-time SBP
and mean DBP values.
Statistical analysis
Data are expressed as mean ± standard deviation (SD).
The statistical analysis of the data was performed by
the statistical analysis software (SAS) system, version
6.12 (SAS Institute, Inc., Cary, NC, USA). The differ-
ences between the two groups in baseline characteris-
tics were analyzed by the two-tailed Student’s t-test.
Comparisons within and between groups were assessed
by a mixed ANOVA. Differences between baseline and
after 6-months’ treatment in each group in BP and
oxidative stress parameters were analyzed with the
Wilcoxon signed rank test. Comparisons of changes in
BP and oxidative stress parameters between the two
groups were performed with the Mann-Whitney U-test
[28]; we adjusted results for potential confounding fac-
tors including SBP. Findings of p < 0.05 were consid-
ered significant. Considering as clinically significant a
difference of at least 10 % compared with the baseline
and an alpha error of 0.05, the actual sample size was




We enrolled 151 patients; 75 were randomised to lerca-
nidipine and 76 to barnidipine (Table 1). One hundred
Fig. 1 CONSORT 2010 Flow Diagram
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and forty-three patients completed the study. Eight
patients did not complete the study and the reasons
for prematurely withdrawal included: lost to follow-up
(3 patients), cough (2 patients), withdrawn of consent
(3 patients) (Fig. 1).
Blood pressure and ABPM
Both barnidipine and lercanidipine resulted in a signifi-
cant reduction in SBP and DBP (p < 0.001 vs baseline for
barnidipine + losartan and p < 0.01 for lercanidipine +
losartan), even if the BP reduction obtained with barni-
dipine + losartan was greater than that obtained with
lercanidipine + losartan (p < 0.05). Data recorded with
ABPM showed a similar trend, even if no differences
were recorded in the descent of the nocturnal blood
pressure of barnidipine and lercanidipine (Table 2).
Oxidative stress parameters
Barnidipine + losartan reduced the levels of Hs-CRP and
TNF-α (p < 0.05 vs baseline and vs lercanidipine + losartan).
There were no significant differences between the two
treatments on the levels of MMP-2 and -9. Barnidipine +
losartan significantly reduced the levels of sVCAM-1 and
sICAM-1 after 6 months of treatment, both compared to
baseline and to lercanidipine + losartan (p < 0.05 for
both). The levels of isoprostanes were reduced by
barnidipine + losartan (p < 0.05 vs baseline and vs
lercanidipine + losartan), while the levels of PON-1
remained unchanged with both treatments (Table 3).
Table 2 Effects of the two treatments on ambulatory blood pressure monitoring
Losartan+barnidipine Losartan+lercanidipine
Baseline End of study Baseline End of study p for interaction between groups
N 75 72 76 71 -
Sex (male/female) 37/38 36/36 36/40 35/36 ns
SBP (mmHg) 150.8 ± 9.7 130.2 ± 5.6** 152.5 ± 10.6 141.9 ± 6.5* 0.041
DBP (mmHg) 96.6 ± 5.4 84.5 ± 5.7** 96.7 ± 5.5 90.4 ± 5.9* 0.039
HR (beats/min) 70.3 ± 7.7 70.1 ± 7.6 72.6 ± 8.1 72.2 ± 7.9 ns
24 h SBP (mmHg) 142.5 ± 10.5 128.8 ± 7.3** 143.2 ± 10.8 134.9 ± 8.5* 0.042
24 h DBP (mmHg) 94.7 ± 7.9 84.5 ± 6.1** 94.3 ± 7.8 89 ± 7.1* 0.045
24 h MBP (mmHg) 118.2 ± 8.0 105.1 ± 6.1* 116.3 ± 7.6 110.3 ± 7.1 ns
Data are means ± SD
SBP systolic blood pressure, DBP diastolic blood pressure, MBP mean blood pressure, HR heart rate
*p < 0.01 vs baseline; **p < 0.001 vs baseline
Table 3 Effects of the two treatments on oxidative stress parameters
Losartan+barnidipine Losartan+lercanidipine
Baseline End of study Baseline End of study p for interaction between groups
N 75 72 76 71 -
Sex (male/female) 37/38 36/36 36/40 35/36 ns
BMI (Kg/m2) 28.5 ± 1.3 28.4 ± 1.2 28.2 ± 1.1 28.1 ± 1.0 ns
Fasting plasma glucose (mg/dl) 129.6 ± 9.7 125.8 ± 9.1 130.1 ± 10.2 127.6 ± 9.9 ns
HbA1c (%) 7.0 ± 0.5 6.9 ± 0.4 6.9 ± 0.4 7.0 ± 0.5 ns
Hs-CRP (mg/l) 1.7 ± 0.9 1.2 ± 0.4* 1.6 ±0.8 1.5±0.6 0.047
TNF-α (ng/ml) 2.9 ± 1.7 2.2 ± 1.3* 2.8 ± 1.6 2.6 ± 1.4 0.042
MMP-2 (ng/ml) 1216.5 ± 124.1 965.1 ± 102.6* 1218.8 ± 126.8 978.3 ± 106.2* ns
MMP-9 (ng/ml) 465.1 ± 50.1 382.5 ± 46.3* 462.2 ± 49.4 394.1 ± 48.5* ns
sVCAM-1 (ng/ml) 637.8 ± 172.5 536.1 ± 112.7* 638.4 ± 173.1 592.7 ± 141.6 0.041
sICAM-1 (ng/ml) 201.5 ± 12.8 174.2 ± 8.1* 204.2 ± 13.3 198.6 ± 11.2 0.046
Isoprostanes (pg/ml) 114.3 ± 39.2 92.5 ± 28.5* 110.2 ± 36.8 103.4 ± 33.2 0.047
PON-1 (U/l) 160.5 ± 85.2 182.5 ± 99.2 157.1 ± 83.4 177.2 ± 95.7 ns
Data are means ± SD
*p < 0.05 vs baseline
BMI body mass index, FPI fasting plasma insulin, HbA1c glycated hemoglobin, Hs-CRP high-sensitivity C-reactive protein, TNF-α tumor necrosis factor-α, MMP-2
metalloproteinase-2, MMP-9 metalloproteinase-9, sVCAM-1 soluble vascular adhesion protein-1, sICAM-1 soluble intercellular adhesion protein-1,
PON-1 paraoxonase-1
Derosa et al. BMC Cardiovascular Disorders  (2016) 16:66 Page 5 of 7
Discussion
Barnidipine, and lercanidipine are both third-generation
CCBs indicated for the treatment of hypertension [11].
In our study they both reduced BP control, with a better
effect of barnidipine compared to lercanidipine, both in
isolated BP measurements and during ABPM. This is in
contrast with what we previously reported [29], where
no differences were recorded between barnidipine and
lercanidipine in reducing blood pressure. This can be
due to the different population enrolled, diabetic hyper-
tensive patients with left ventricular hypertrophy in the
first study and diabetic hypertensive patients in the
current trial. Regarding pleiotropic effects of these
drugs, barnidipine is a new dihydropyridinic calcium
antagonist with long-lasting vasodilator properties [30]
in the absence of sympathetic activation [31], possible
anti-oxidant effects [25], a slight beneficial effect on
lipid profile [32], and a good effect on insulin sensitivity
[33]. Also lercanidipine seems to give a reduction of
white blood cells and peripheral polymorphonuclear
leukocytes counts, of peripheral polymorphonuclear
leukocytes apoptosis, and of C-reactive protein in
hypertensive patients [34]. In our study, only barnidi-
pine gave a decrease of Hs-CRP, TNF-α, sVCAM-1 and
sICAM-1, both compared to baseline and lercanidipine.
The better effect of barnidipine on endothelial damage
markers compared to lercanidipine can be only partially
explained by the greater BP reduction, because, after
adjusting results for potential confounding factors in-
cluding SBP, it does not seem to influence the results.
This seems to suggest an intrinsic effect of the drug on
endothelial damage markers.
On the other hand, isoprostanes are prostaglandin-like
compounds formed in vivo from the free radical-
catalyzed peroxidation of essential fatty acids, primarily
arachidonic acid, without the direct action of cyclooxy-
genase enzymes. Isoprostane levels represent reliable
markers of oxidative stress. Barnidipine administration
caused a significant reduction of isoprostane levels, in
line with what already reported by Spirou et al. [25].
Paraoxonase-1, instead, is synthesized in the liver and
transported along with HDL in the plasma. It functions
as an anti-oxidant; it prevents the oxidation of LDL. Its
serum concentration is influenced by inflammatory
changes and the levels of serum oxidised-LDL. In our
study we did not record an effect of anti-hypertensive
drug on this parameter.
We have already compared barnidipine and lercanidi-
pine effects on echocardiographic parameters [29], how-
ever, this is, at our knowledge, the first study to directly
compare the effects of two different CCBs on inflamma-
tion. Of course our study has some limitations, as the
short study duration; moreover we did not assess esti-
mated glomerular filtration rate variation during the
study, and evaluated only some inflammatory markers,
focusing our attention on a few of them.
Conclusions
In addition to giving a greater reduction of BP, barnidi-
pine + losartan gave an improvement of some parame-
ters indicative of endothelial damage and oxidative stress
in diabetic and hypertensive patients.
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